ISRCTN88164211 https://doi.org/10.1186/ISRCTN88164211

Pathophysiology of Dupuytren's Contracture

Submission date	Recruitment status	[ ] Prospectively registered
11/08/2010	No longer recruiting	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
11/08/2010	Completed	[ ] Results
Last Edited	**Condition category**	[ ] Individual participant data
18/04/2017	Musculoskeletal Diseases	[ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr Liaquat Suleman-Verjee

Contact details
Imperial College London
Kennedy Institute of Rheumatology Division
65 Aspenlea Road
London
United Kingdom
W6 8LH

Additional identifiers

Protocol serial number
6585

Study information

Scientific Title
Pathophysiology of Dupuytren's Contracture

Study objectives
Dupuytren's disease is a common inheritable disorder, mainly affecting the hand. The digits develop progressive flexion contractures and hand function is significantly impaired. The current mainstay of treatment is surgical excision of the affected tissues but recurrence following

excision is seen in approximately 40% of patients. Replacing the palmar skin with grafts obtained from a non-palmar site on the body virtually abolishes recurrence. Based on this well-established surgical observation, we have developed a novel in vitro model that replicates these interactions between skin cells and the contractile cells responsible for Dupuytren's disease. We have also identified a molecule (tenascin-C) that may control the signalling between these cell types.

Ethics approval required
Old ethics approval format

Ethics approval(s)
MREC approved, ref: 06/Q0403/95

Study design
Multicentre non-randomised interventional treatment trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Topic: Generic Health Relevance and Cross Cutting Themes; Subtopic: Generic Health Relevance (all Subtopics); Disease: Surgery

Interventions
Elucidate the exact role of tenascin-C in Dupuytren's disease

Intervention Type
Other

Phase
Not Specified

Primary outcome(s)
Develop candidate therapeutic target to provide non-surgical intervention to modulate the disease

Key secondary outcome(s))
Not provided at time of registration

Completion date
31/07/2011

Eligibility

Key inclusion criteria
Not provided at time of registration

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Not Specified

Sex
Not Specified

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
02/11/2006

Date of final enrolment
31/07/2011

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Imperial College London
London
United Kingdom
W6 8LH

Sponsor information

Organisation
Royal College of Surgeons of England (UK)

ROR
https://ror.org/02qrg5a24

Funder(s)

Funder type
Charity

Funder Name
Healing Foundation

Alternative Name(s)

Funding Body Type
Private sector organisation

Funding Body Subtype
Other non-profit organizations

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes